FDA Advisors Recommend Approval Of Taxol for Node-Positive Breast Cancer
In Brief: Justice Department Files Civil Suit To recover $25 Billion From Tobacco
ODAC Actions: Large Subset analysis Of CALGB Study Was Basis for BMS Taxol Application
UFT – Leucovorin Combo Not A Breakthrough, But could Merit Approval, Committee Says
Roferon A Application Marred By Mission Data, Protocol, Compliance
Underpowered Study Of Evacet Dashes Approval Hopes
NCI Programs: Institute Funds 24 DNA Microarray Centers
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - Brian Wolpin celebrates FDA approval of daraxonrasib in pancreatic cancer as the future of the field
- The end of “more money, more people, more trials”
Cancer centers are being asked to grow their portfolios on flat budgets. Headcount is the wrong answer. - Harold Freeman, a surgeon who championed health equity, dies at 93
Freeman, the father of patient navigation, served as president of ACS and chair of the President’s Cancer Panel - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
